WHO ICTRP trial
INTERACT stomach-II
CTIS2025-521468-36-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2025-521468-36-00 |
|---|---|
| Public title | INTERACT stomach-II |
| Scientific title | Intraperitoneal irinotecan combined with systemic therapy for patients with gastric peritoneal metastases: A phase II, multicenter study |
| Primary sponsor | Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | Netherlands |
| Conditions | Gastric peritoneal metastases;Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Interventions | Product Name: Irinotecan Accord 20 mg/ml concentraat voor oplossing voor infusie, Product Code:PRD4362142, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: |
| Registration date | May 26, 2025 |
| Target size | 49 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: